Proteome Sciences plc Board Appointment

Proteome Sciences plc (LON:PRM) has today announced that Mr Richard Dennis has today been appointed to the Board of Directors.  As communicated on 3 April 2017, when he joined the Company as its first Chief Commercial Officer, Mr Dennis has over 30 years’ experience in the sector gained most recently as Director of International Commercial Operations at Quanterix Corp, and prior to that in positions of increasing responsibility at Bioscale Inc. and Meso Scale Discovery.

 

Commenting on this appointment, Jeremy Haigh, Chief Executive Officer, said“I am delighted to welcome Richard to the Board. Since joining a year ago Richard has transformed our commercial identity and ambition with his focus on face to face selling, account management, and an established client network across Europe.  His arrival heralded a relaunch of our services business and inspired a complete review of our commercial practice resulting in the adoption of an agent-based sales model in our principal operating territories.  His deep experience of strategic sales and marketing within the bioscience sector will be an asset to the Board at this critical juncture in the Company’s development”

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Share on facebook
    Facebook
    Share on twitter
    Twitter
    Share on linkedin
    LinkedIn
    Proteome Sciences Plc

    More articles like this

    Proteome Sciences Plc

    Proteome Sciences plc License Agreement Extension

    Electrophoretics Ltd, a wholly owned subsidiary of Proteome Sciences plc (LON:PRM), is pleased to announce that it has signed an amendment to the exclusive License and Distribution Agreement with Pierce Biotechnology Inc., a part of Thermo Fisher Scientific Inc.,

    Proteome Sciences Plc

    Proteome Sciences plc Notice of Results

    The Directors look forward to updating shareholders on the Company’s performance, and on the outlook for 2018, at the time they announce their 2017 full year results which are scheduled for release on 24 April 2018.  Annual General

    Proteome Sciences Plc

    Proteome Sciences plc accreditation for clinical stage contracts

    Proteome Sciences plc has this morning announced the receipt of Good Clinical Laboratory Practice (GCLP) accreditation which will now enable it to compete effectively for clinical stage contracts commanding routinely larger budgets; the benefits of this should start

    Proteome Sciences Plc

    Proteome Sciences sales and royalties have increased 40%

    Proteome Sciences LON:PRM has given DirectorsTalk its unaudited interim results for the six months ended 30 June 2017. Financial highlights: — Total revenues increased 21% to GBP1.36m (2016: GBP1.12m) — TMT(R) reagent sales and royalties increased 40% to